Jasper Therapeutics (NASDAQ:JSPR) Director Purchases $99,630.00 in Stock

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Director Thomas Wiggans purchased 41,000 shares of Jasper Therapeutics stock in a transaction dated Monday, September 22nd. The shares were acquired at an average cost of $2.43 per share, with a total value of $99,630.00. Following the transaction, the director directly owned 41,000 shares in the company, valued at approximately $99,630. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $2.33 on Friday. The firm has a 50 day moving average of $2.80 and a 200 day moving average of $4.14. The firm has a market capitalization of $37.86 million, a price-to-earnings ratio of -0.39 and a beta of 2.77. Jasper Therapeutics, Inc. has a 12-month low of $2.21 and a 12-month high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Wednesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.54). On average, analysts predict that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. UBS Group cut their price objective on shares of Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a report on Friday, August 15th. William Blair reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a report on Monday, July 7th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a report on Tuesday, July 8th. HC Wainwright cut their price objective on shares of Jasper Therapeutics from $40.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 7th. Finally, Royal Bank Of Canada lowered shares of Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 target price for the company. in a report on Tuesday, July 8th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Jasper Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $25.63.

Institutional Trading of Jasper Therapeutics

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the first quarter worth $46,000. Marex Group plc bought a new stake in Jasper Therapeutics in the second quarter worth $74,000. Engineers Gate Manager LP bought a new stake in Jasper Therapeutics in the second quarter worth $78,000. Corton Capital Inc. bought a new stake in Jasper Therapeutics in the first quarter worth $113,000. Finally, Wellington Management Group LLP lifted its position in Jasper Therapeutics by 13.9% in the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock worth $579,000 after buying an additional 3,310 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.